Detail akcie Alteri Thera Sp ADS online

Business Summary: Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Financial Summary: BRIEF: For the fiscal year ended 30 June 2025, Alterity Therapeutics Ltd (ADR) revenues increased 66% to A$446K. Net loss decreased 36% to A$12.1M. Revenues reflect Reaserch and development in the field of Paekinsonaian movem segment increase of 66% to A$893K. Lower net loss reflects Other research and development expenses decrease of 26% to A$12M (expense), Miscellaneous Income increase from A$0K to A$2.2M (income).